Back to Search
Start Over
Prognostic impact of pretherapeutic gamma-glutamyltransferase on patients with nasopharyngeal carcinoma
- Source :
- PLoS ONE, Vol 12, Iss 2, p e0172345 (2017), PLoS ONE
- Publication Year :
- 2017
- Publisher :
- Public Library of Science (PLoS), 2017.
-
Abstract
- Background Gamma-glutamyltransferase (GGT) is a membrane-bound enzyme involved in the metabolism of glutathione. Studies suggested that GGT played an important role in the tumor development, progression, invasion and drug resistance and prognosis. The association between GGT and prognosis of patients with nasopharyngeal carcinoma (NPC) was unknown. This study was conducted to investigate the association of pretherapeutic serum level of GGT with clinical-pathological parameters and survival in patients with NPC. Methods Two hundred and twenty-two patients with NPC were recruited in this study and were stratified into two GGT risk groups (≤ 34.5 U/L, > 34.5 U/L). The association of pretherapeutic serum GGT levels with clinical–pathological parameters was examined. Univariate and multivariate survival analyses were performed. Findings The pretherapeutic serum level of GGT was not associated with gender, age, pathology, T stage, N stage, TNM stage, chemotherapy or radiotherapy in patients with NPC. Patients in the high-risk GGT group had a poorer survival than the low-risk GGT group (3-year overall survival, 74.2% vs. 50.2%, P = 0.001; 3-year progression-free survival, 76.4% vs. 47.1%, P < 0.001; 3-year loco-regional relapse-free survival, 76.4% vs. 51.3%, P < 0.001; 3-year distant metastasis-free survival, 89.5% vs. 66.4%, P < 0.001). Multivariate analysis suggested that patients in the high-risk GGT group had 2.117 (95% confidence interval [CI], 1.225 ∼ 3.659, P = 0.007) times the risk of death, 2.836 (95% CI, 1.765 ∼ 4.557, P < 0.001) times the risk of progression, 2.551 (95% CI, 1.573 ∼ 4.138, P < 0.001) times the risk of relapse, and 3.331 (95% CI, 1.676 ∼ 6.622, P < 0.001) times the risk of metastasis compared with those in the low-risk GGT group. Conclusion The pretherapeutic serum level of GGT might serve as a novel independent prognostic factor for overall-survival, progression-free survival, loco-regional relapse-free survival and distant metastasis-free survival in patients with NPC.
- Subjects :
- 0301 basic medicine
Male
medicine.medical_treatment
Cancer Treatment
lcsh:Medicine
Drug resistance
Kaplan-Meier Estimate
Gastroenterology
Biochemistry
Metastasis
0302 clinical medicine
Mathematical and Statistical Techniques
Basic Cancer Research
Medicine and Health Sciences
Stage (cooking)
Gamma-glutamyltransferase
Neoplasm Metastasis
lcsh:Science
Multidisciplinary
Nasopharyngeal Carcinoma
biology
Pharmaceutics
Liver Neoplasms
gamma-Glutamyltransferase
Middle Aged
Prognosis
Magnetic Resonance Imaging
Glutathione
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Physical Sciences
Disease Progression
Female
Statistics (Mathematics)
Research Article
Adult
Clinical Oncology
medicine.medical_specialty
Radiation Therapy
Research and Analysis Methods
Carcinomas
digestive system
Disease-Free Survival
03 medical and health sciences
Cancer Chemotherapy
Drug Therapy
Diagnostic Medicine
Internal medicine
medicine
Humans
Chemotherapy
Statistical Methods
business.industry
Carcinoma
lcsh:R
Cancers and Neoplasms
Biology and Life Sciences
Nasopharyngeal Neoplasms
medicine.disease
Confidence interval
digestive system diseases
030104 developmental biology
Nasopharyngeal carcinoma
ROC Curve
Drug Resistance, Neoplasm
Multivariate Analysis
biology.protein
T-stage
lcsh:Q
Neoplasm Recurrence, Local
Clinical Medicine
business
Peptides
Mathematics
Subjects
Details
- Language :
- English
- ISSN :
- 19326203
- Volume :
- 12
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- PLoS ONE
- Accession number :
- edsair.doi.dedup.....d293c21459b80f6984ea23921df55749